The present feasibility study was designed to obtain a monolayer patch containing oxybutynin (OXY) avoiding chemical permeation enhancer. The highest flux was obtained with a polydimethylsiloxane matrix patch. Because OXY crystals were detected in the matrix within a week, two amino methylmethacrylate copolymers (Eudragit E or Eudragit RS) were used as OXY crystallization inhibitors. A preliminary in vivo study indicate that flux from the stabilized patches had to be increased about 30-40%. This goal was reached by occlusion with a polyethylene layer
Formulation study of oxybutynin patches / P. Minghetti, F. Cilurzo, S. Pagani, A. Casiraghi, R. Assandri, L. Montanari. - In: PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY. - ISSN 1083-7450. - 12:3(2007), pp. 239-246.
Formulation study of oxybutynin patches
P. MinghettiPrimo
;F. CilurzoSecondo
;S. Pagani;A. Casiraghi;L. MontanariUltimo
2007
Abstract
The present feasibility study was designed to obtain a monolayer patch containing oxybutynin (OXY) avoiding chemical permeation enhancer. The highest flux was obtained with a polydimethylsiloxane matrix patch. Because OXY crystals were detected in the matrix within a week, two amino methylmethacrylate copolymers (Eudragit E or Eudragit RS) were used as OXY crystallization inhibitors. A preliminary in vivo study indicate that flux from the stabilized patches had to be increased about 30-40%. This goal was reached by occlusion with a polyethylene layer
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
